BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15933480)

  • 1. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Gasquet I; Haro JM; Novick D; Edgell ET; Kennedy L; Lepine JP;
    Int Clin Psychopharmacol; 2005 Jul; 20(4):199-205. PubMed ID: 15933480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Novick D; Haro JM; Perrin E; Suarez D; Texeira JM
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):542-50. PubMed ID: 19500949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I; Czobor P; Dossenbach M; Volavka J
    Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.
    Lee C; Wu KH; Habil H; Dyachkova Y; Lee P
    Aust N Z J Psychiatry; 2006 May; 40(5):437-45. PubMed ID: 16683970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
    Ritsner M; Gibel A; Perelroyzen G; Kurs R; Jabarin M; Ratner Y
    J Clin Psychopharmacol; 2004 Dec; 24(6):582-91. PubMed ID: 15538118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
    Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
    Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
    Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
    Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Dyachkova Y; Pirildar S; Anders M; Khalil A; Araszkiewicz A; Shakhnovich T; Akram A; Pecenak J; McBride M; Treuer T
    Eur Psychiatry; 2006 Jun; 21(4):251-8. PubMed ID: 16530390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.